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clinical practice despite only limited evidence.Methods All 516 CT scans that involved direct radiation exposure of CRM devices (332 deﬁbrillators, 184 pacemakers) at
2 large-volume centers between July 2000 and May 2010 were included. The primary outcome was a composite
endpoint of death, bradycardia or tachycardia requiring termination of the scan or an immediate intervention,
unplanned hospital admission, reprogramming of the device, inappropriate deﬁbrillator shocks, or device
replacement/revision thought to be due to CT imaging. Signiﬁcant changes in device parameters were sought
as a secondary outcome (control group 4:1 ratio).Results The main ﬁnding was that none of the CTs were associated with the primary outcome. With serial device
interrogations, there were no differences in changes in battery voltage or lead parameters between devices exposed
to radiation and their controls. Potentially signiﬁcant changes in device parameters were observed in a small group
of devices (both the CT group and control group), but no deﬁnitive link to CT was conﬁrmed, and there were no
associated clinical consequences.Conclusions The ﬁndings suggest that the presence of CRM devices should not delay or result in cancellation of clinically
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re-evaluated. (J Am Coll Cardiol 2014;63:1769–75) ª 2014 by the American College of Cardiology FoundationComputed tomography (CT) imaging has been traditionally
considered to be safe in patients with cardiac rhythm man-
agement (CRM) devices such as permanent pacemakers
(PPMs) or implantable cardioverter-deﬁbrillators (ICDs).
It has been suggested in few experimental studies with an-
thropomorphic phantoms and very limited in vivo data that
CT irradiation might affect the functioning of CRM devices
(1–4). Subsequently, on the basis of these observations and a
few individual reports, the U.S. Food and Drug Adminis-
tration (FDA) released, on July 14, 2008, a public healthardiology Imaging Group (MACIG), Division
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013; revised manuscript received December 4,notiﬁcation warning that exposure to x-ray radiation during
CT scanning may interfere with the proper functioning
of some electronic devices, including PPMs and ICDs (2).
See page 1776
In the original FDA report, potential problems from
CT imaging included unintended shocks, transient changes
in pacemaker output pulse rate, generation of spurious sig-
nals (including cardiac deﬁbrillation pulses), misinter-
pretation of signals produced by the x-rays as actual
biological signals, missed detection of actual biological sig-
nals, and resetting or reprogramming of device settings (2).
Although on the basis of only limited peer-reviewed evi-
dence, speciﬁc recommendations made by the FDA
included having a physician ready to take emergency mea-
sures to manage adverse events should they occur, as well
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1770having the device checked after
CT imaging to ensure proper
function. To date, this represents
the only advisory from a regula-
tory agency worldwide to have
addressed such interference.
The 2008 FDA report and
recommendations raised con-
cerns in the medical community
due to a lack of signiﬁcant peer-
reviewed evidence, the potential
to affect quality of care by avoiding
medically necessary CT scans, as
well as the potential to divert
health care costs by implementingsafety policies and procedures that have not been demonstrated
to be appropriate or necessary (5).
No published data currently exist regarding the signiﬁ-
cance of CT interference with CRM devices in clinical
practice. Speciﬁcally, no data exist regarding the occurrence
in clinical practice of inappropriate shocks from ICDs,
reprogramming of device settings, or other clinically signif-
icant events. This study sought to assess the occurrence
of CT-related device interactions mentioned in the 2008
FDA advisory.
Methods
The study was performed at the University of Maryland
Medical Center (Baltimore, Maryland) and the Balti-
more Veterans Administration Medical Center (Baltimore,
Maryland) and was approved by the institutional review
boards at both institutions. All CRM devices directly
exposed to radiation beams from CT imaging between July
2000 and May 2010 were included. The CT scans were
performed using the Philips 4, 16, and 64-slice multi-
detector (Philips, Best, the Netherlands) at the University of
Maryland Medical Center and the SOMATOM Sensation
16 and 64 (Siemens, Erlangen, Germany) at the Baltimore
Veterans Administration Medical Center.
Primary outcome: adverse clinical events. The primary
outcome of interest was a composite endpoint of death,
bradycardia or tachycardia requiring termination of the scan
or an immediate intervention, unplanned hospital admissions,
inappropriate ICD shocks, resetting or reprogramming of
device settings, or device replacement/revision thought to
be secondary to radiation exposure from CT imaging. A
careful review of medical records was conducted to identify
adverse device-related clinical events that may have happened
as a consequence of exposure to radiation from CT imaging.
This was achieved by reviewing all clinical documentation
before and up to the time of device interrogation in the
outpatient clinic after CT exposure. This included review of
outpatient and inpatient clinical notes, CT scan reports, and
hospital discharge summaries. In patients who had deviceinterrogation performed within 2 months after CT exposure,
additional review of records was performed up to the time of
the second post-CT visit to the device clinic.
Secondary outcome: changes in device parameters. The
secondary endpoint of interest was the occurrence of sig-
niﬁcant changes in device parameters that could have po-
tential clinical signiﬁcance. These changes were deﬁned a
priori as any of the following: 1) unexpected decrease in
battery power; 2) lead failure to pace or sense; 3) increase or
decrease in lead impedance by 50% or more; 4) decrease
of R-wave sensing by 50% or a ﬁnal sensitivity <2 mV
(potentially compromising detection of life-threatening ar-
rhythmia by ICDs); and 5) doubling of threshold amplitude
to a voltage >2 V, tripling of pulse width with a follow-up
value >0.4 ms (potentially leading to inability to pace
assuming minimally programmed pacing parameters of 2 V
at 0.4 ms), or change by 50% or more in threshold product
(deﬁned as threshold amplitude [V] multiplied by pulse
width [ms] to account for pre-/post-CT interrogations using
alternating voltage and pulse width decreases).
For every CT scan performed, device lead and function
parameters were obtained from 2 consecutive device in-
terrogations conducted prior to and after CT scanning.
When multiple CT scans were performed between consec-
utive interrogations, the CTs were counted as a single entry
into the serial assessment of device parameters. Given that
small changes in device parameters could occur over time
under normal circumstances, a control group was also
studied to better assess the secondary endpoint. For every
four devices exposed to direct radiation beams from CT
scans, one control device with no exposure to CT imaging
was included for comparison (closest time-match of pre-CT
interrogation for every fourth device). Control subjects had
to have 2 consecutive interrogations available to allow
analysis of changes in device parameters. With analysis of
parameters from consecutive device interrogation sessions,
changes in battery voltage, lead impedance, thresholds, or
sensitivities were determined, and patients with potentially
signiﬁcant changes were subsequently identiﬁed. All patients
who underwent device revisions after CT scanning but
before the follow-up interrogation were also identiﬁed, and
the indications for device revisions were carefully reviewed,
with a focus on differentiating planned from unplanned
revisions.
Statistical analysis. All statistical analyses were performed
using JMP Pro version 10.0 (SAS Institute Inc., Cary,
North Carolina). Numbers are presented as mean  SD or
median (interquartile range [IQR]), as appropriate. Serial
changes in device parameters are reported as absolute values
and as percent changes from baseline. The chi-square test and
Student t test were employed for comparison of proportions
or means, respectively, between 2 groups. For non-normally
distributed variables, a nonparametric test (Wilcoxon rank
sum test) was employed. A 2-sided p value <0.05 was
considered statistically signiﬁcant.
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Between July 2000 and May 2010, all 516 CT scans that
involved exposure of CRM devices (332 ICDs, 184 PPMs)
to direct radiation beams from CT imaging were included.
The indications for which the CTs were performed are
summarized in the Online Table. These CT scans were
performed in 386 patients (241 with ICDs, 145 with
PPMs) and most (292 patients [75.6%]) underwent only one
CT scan (71 patients had 2 scans, 15 had 3, 4 had 4, 3 had 5,
and 1 had 6 scans between July 2000 and May 2010). The
mean age was 63.7  16.4 years, and 81.1% of the patients
were men. Comorbid conditions included coronary artery
disease (69.2%), systemic hypertension (53.1%), and diabetes
mellitus (29.3%). In 94 patients who underwent more than
one CT, the scans were 14 months apart (IQR: 10 to 39
months), and 29 had 2 or more scans between consecutive
device interrogations (23 had 2, 5 had 3, and 1 had 4). The
baseline characteristics of the devices exposed to CT imaging
are summarized in Table 1. The control group, which was
included for assessment of the secondary endpoint, consisted
of 129 devices (83 ICDs, 46 PPMs) in 129 patients who did
not undergo CT imaging.
Of 332 ICDs exposed to radiation, the device manu-
facturers were Medtronic, Inc. (Minneapolis, Minnesota)
(45.8%), Guidant/Boston Scientiﬁc (Natick, Massachusetts)
(38.3%), St. Jude Medical, Inc. (St. Paul, Minnesota)
(13.9%), and other manufacturers (2.1%) (vs. 59.0%, 34.9%,
4.8%, and 1.2%, respectively, in control group; p¼ 0.04). Of
the ICDs exposed to CT, 56.6% were single-chamber de-
vices, 26.8% were dual-chamber devices, and 16.6% wereTable 1
Baseline Characteristics of CRM Devices Exposed
to Direct Radiation Beams From CT
ICD
(n ¼ 332)
PPM
(n ¼ 184)
Manufacturer
Medtronic 45.8 57.1
Guidant/Boston Scientiﬁc 38.3 21.2
St. Jude 13.9 20.7
Other 2.1 1.1
Chambers
Single 56.6 14.7
Dual 26.8 85.3
Biventricular 16.6 0.0
Indication for implantation
Primary prevention 55.4 d
Secondary prevention 36.5 d
Atrioventricular block d 42.9
Symptomatic sinus bradycardia d 21.2
Sick sinus/atrial ﬁbrillation d 2.7
Unknown 8.1 24.5
Other 0.0 8.7
Values are % of devices.
CRM ¼ cardiac rhythm management; CT ¼ computed tomography; ICD ¼ implantable
cardioverter-deﬁbrillator; PPM ¼ permanent pacemaker.biventricular (vs. 56.6%, 27.7%, and 15.7% in control group;
p ¼ 0.97). Of 184 PPMs exposed to radiation, the device
manufacturers were Medtronic, Inc. (57.1%), Guidant/
Boston Scientiﬁc (21.2%), St. Jude Medical, Inc. (20.7%),
and other manufacturers (1.1%) (vs. 52.2%, 23.9%, 21.7%,
and 2.2% in control group; p ¼ 0.90). Of the PPMs exposed
to CT, 14.7% were single-chamber devices and 85.3% were
dual-chamber devices (vs. 21.7% and 78.3% in control
group; p ¼ 0.26).
Baseline device interrogation results were available for
all devices. All but 6 devices in the CT group had available
follow-up interrogations (3 deaths with heart failure [none
with a biventricular device], 2 deaths with overwhelming
sepsis, and 1 loss to follow-up in the device clinic but had
followed up with the primary care physician). An extensive
review of the medical records of death cases did not suggest
any device dysfunction or a direct or indirect link of fatality
to CT scanning.
Primary outcome: adverse clinical events. The primary
outcome was not observed in any of the patients who
underwent CTs that involved direct radiation exposure
of CRM devices. Speciﬁcally, there were no deaths,
bradycardia or tachycardia requiring termination of the
scan or an immediate intervention, unplanned hospital
admissions, inappropriate ICD shocks, or device replace-
ment/revision thought to be secondary to radiation expo-
sure during CT imaging. No clinically evident device
malfunction during CT imaging was documented. Three
patients in the CT group were PPM dependent, but no
adverse events were noted. Further review of medical re-
cords showed that none of the patients had received a
perfusion or interventional CT imaging that could have
exposed the device to radiation beams for longer than a few
seconds. Arrhythmic events such as atrial ﬁbrillation (mode
switching), ventricular tachycardia, or ICD therapy were
recorded on 32.0% of post-CT interrogations (vs. 33.1% of
pre-CT interrogations; p ¼ 0.69). The time stamps of these
arrhythmic events were compared with CT timing, and
there was no temporal association or new arrhythmias. No
spontaneous resetting or reprogramming of device settings
was observed.
Secondary outcome: changes in device parameters. Serial
device interrogations were reviewed to assess changes in
device settings. In the group of ICDs exposed to CT,
the median (IQR) time interval between initial and follow-
up interrogations was 119 (91 to 194) days (vs. 98 [91 to
128] days in control group; p ¼ 0.02). The follow-up in-
terrogations in this group occurred 72 (56 to 83) days after
CT exposure. In the group of PPMs exposed to CT, follow-
up interrogations occurred 186 (164 to 229) days after the
initial visits (vs. 182 [122 to 207] days in control group; p ¼
0.29) and 92 (72 to 105) days after CT scans. The baseline
and changes from baseline in parameters of ICDs and PPMs
exposed to CT and their controls are summarized in
Table 2. Overall, there were no signiﬁcant differences in
Table 2 Changes in Parameters of CRM Devices Exposed to Direct Radiation Beams From CT
ICD PPM
CT
(n ¼ 332)
Control
(n ¼ 83) p Value
CT
(n ¼ 184)
Control
(n ¼ 46) p Value
Battery power
Baseline, V 3.0  0.2 3.0  0.2 0.80 2.8  0.1 2.8  0.1 0.11
Absolute change, V –0.05  0.07 –0.02  0.04 0.02 –0.05  0.3 –0.00  0.02 0.18
Absolute change per month, V –0.01  0.03 –0.01  0.02 0.13 –0.01  0.03 –0.00  0.01 0.12
% Change –1.5  2.5 –0.8  1.4 0.02 –1.9  11.0 –0.1  0.6 0.18
% Change per month –0.32  0.81 –0.16  0.49 0.12 –0.2  1.2 –0.00  0.2 0.12
RV lead
Impedance
Baseline, U 558.6  206.4 510.9  142.4 0.05 627.6  213.7 621.5  260.5 0.89
Absolute change, U –11.3  98.3 þ5.2  49.7 0.11 –4.7  65.1 –8.7  106.8 0.82
% Change –0.4  13.3 þ1.4  8.0 0.23 –1.6  9.7 –3.1  12.9 0.58
Sensitivity
Baseline, mV 11.7  5.2 11.7  5.2 1.00 10.2  4.4 10.7  4.6 0.66
Absolute change, mV þ0.2  3.6 –0.4  2.9 0.26 þ0.3  4.6 –0.5  3.0 0.34
% Change þ29.8  239.1 –0.4  29.0 0.18 11.8  50.3 –0.6  23.4 0.13
Threshold product
Baseline, Vms 0.25 (0.15 to 0.40) 0.40 (0.23 to 0.50) 0.005 0.28 (0.20 to 0.40) 0.30 (0.20 to 0.40) 0.58
Absolute change, Vms 0.02  0.60 þ0.01  0.24 0.82 –0.00  0.18 –0.06  0.49 0.45
% Change þ84.4  327.6 þ15.7  84.2 0.03 18.6  83.3 þ2.5  44.0 0.14
RA lead
Impedance
Baseline, U 488.1  101.8 509.2  90.9 0.30 558.8  225.6 547.1  175.5 0.76
Absolute change, U þ36.3  280.7 –14.7  44.8 0.18 þ22.6  179.9 –9.4  49.4 0.13
% Change þ10.6  79.2 –2.7  8.3 0.21 þ5.9  46.7 –1.6  7.9 0.15
Sensitivity
Baseline, mV 3.6  1.7 3.4  1.5 0.60 3.1  1.6 3.7  1.7 0.12
Absolute change, mV –0.2  1.3 þ0.1  1.0 0.27 þ0.01  1.2 –0.5  1.1 0.04
% Change 2.6  41.3 þ11.9  33.7 0.30 þ10.0  57.6 –11.2  28.4 0.02
Threshold product
Baseline, Vms 0.25 (0.15 to 0.40) 0.30 (0.20 to 0.40) 0.40 0.30 (0.20 to 0.40) 0.20 (0.15 to 0.30) 0.003
Absolute change, Vms –0.04  0.29 þ0.03  0.20 0.22 –0.02  0.38 –0.01  0.12 0.78
% Change þ25.8  122.2 þ18.4  59.8 0.74 þ28.4  115.1 þ7.0  48.4 0.19
CS lead
Impedance
Baseline, U 464 (368 to 538) 472 (368 to 511) 0.90 d d d
Absolute change, U –8 (–36 to þ6) þ8 (–29 to þ24.3) 0.20 d d d
% Change –1.8 (–6.9 to þ1.4) þ1.9 (–6.3 to þ1.9) 0.20 d d d
Sensitivity
Baseline, mV 16.7 (6.4 to 24.1) 16.9 (6.6 to 25.2) 0.70 d d d
Absolute change, mV –0.5 (–1.8 to þ1.3) –1.3 (–2.0 to þ0.7) 0.60 d d d
% Change –2.1 (–29.7 to þ13.9) –5.0 (–30.1 to þ8.2) 0.60 d d d
Threshold product
Baseline, Vms 0.19 (0.11 to 0.26) 0.18 (0.15 to 0.30) 0.90 d d d
Absolute change, Vms –0.08  0.31 þ0.01  0.08 0.32 d d d
% Change þ10.6  79.6 þ1.2  29.8 0.68 d d d
Values are mean  SD or median (interquartile range).
CS ¼ coronary sinus; RA ¼ right atrial; RV ¼ right ventricular; Vms ¼ volts  milliseconds; other abbreviations as in Table 1.
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from CT scans and their controls.
With analyses of serial changes in device parameters,
clinically signiﬁcant changes in device parameters or device
compromise were sought. These included unexpected
decrease in battery power and large changes in leadimpedance, threshold, or sensitivity, as previously deﬁned
in Methods section.
Among the devices exposed to CT, there was 1 un-
planned system extraction and 2 unplanned lead revi-
sions. One PPM and its leads were extracted because of
endocarditis and evidence of vegetation on the atrial lead.
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had migrated through the right ventricular apex prior to CT.
The second case involved failure of an epicardial lead to
capture or sense following an open heart aortic valve surgery
with 2 perioperative CTs performed. The lead was found to
have been detached and was reattached, with subsequent
normal functioning.
Three leads were found to have doubling or halving
of impedance values among devices exposed to radiation (1
atrial, 2 ventricular, vs. none in the control group). Further
review showed that doubling of impedance of the atrial lead
was related to a lead fracture that occurred prior to CT.
The 2 ventricular leads with signiﬁcant changes in lead
impedance were fresh implants with initial impedance
values of 1,598 and 879 U and post-CT impedance values
of 662 and 424 U, respectively. Subsequent interrogation
showed stable impedances and normal functioning of the
leads.
Among the devices exposed to CT, 10 leads (1.9%) were
found to have signiﬁcant changes in threshold values (vs.
8 leads in the control group [6.2%]), but none of these
resulted in any clinical consequences. Finally, 1 ICD lead
had a decrease in sensing by more than 50%, with a ﬁnal
value <2 mV (1.5 mV, decreased from 3.1 mV), which was
discovered 118 days after CT exposure but was found to
be in its original range on subsequent interrogations.
Discussion
To our knowledge, this study is the ﬁrst to assess in a large
cohort possible adverse clinical events that could have
resulted from exposure of CRM devices to radiation beams
during CT imaging. Despite an FDA advisory that warned
about possible interactions and made speciﬁc recommen-
dations for acute and follow-up management, no prior
studies have addressed this issue in a large-scale population,
and no data exist regarding the clinical signiﬁcance of such
interaction.
The most important ﬁnding was that the direct expo-
sure of a large number of devices to direct radiation beams
from CT imaging was not associated with clinically sig-
niﬁcant adverse events. Speciﬁcally, there were no deaths,
bradycardia or tachycardia requiring termination of the
scan or an immediate intervention, unplanned hospital
admissions, reprogramming of the device, inappropriate
ICD shocks, or device replacement/revision thought to be
secondary to radiation exposure during CT imaging.
Importantly, these ﬁndings were observed in a 10-year
experience of 2 large-volume tertiary care centers. Addi-
tionally, radiation exposure of ICDs or PPMs did not
appear to have been associated with clinically signiﬁcant
changes in device battery voltage or lead parameters.
Potentially signiﬁcant changes in device parameters were
observed in a small group of devices, but no deﬁnitive link
to CT was conﬁrmed. Accordingly, similar changes were
also observed in a group of devices that were not exposedto CT. Importantly, these changes did not result in any
clinical events.
The original 2008 FDA advisory warned about possible
interference of CT imaging with the proper functioning of
some electronic devices, including the possibility of unin-
tended deﬁbrillator shocks and reprogramming of ICD or
PPM settings (2). The FDA report made speciﬁc recom-
mendations that included having a physician ready to take
emergency measures to manage potential adverse events,
as well having the device checked after CT imaging to
ensure proper functioning. In clinical practice, however,
CT imaging is performed without special considerations
for CRM devices, and routine device interrogations after
CT imaging are not currently the standard of care. None-
theless, incorporating these recommendations into clinical
practice would be logistically challenging and would require
a signiﬁcant amount of resources given the exponential
growth of CT use in the past two decades.
In fact, the number of CT services billed to Medicare
has grown exponentially, and millions of CT procedures
are performed every year in the United States alone (6).
Importantly, the number of CTs that may involve direct
exposure of CRM devices to radiation beams has signiﬁcantly
increased (6,7), with evidence that CTs of the chest are
consistently in the top 10 most frequently billed advanced
imaging procedures (6), and of all advanced cardiac imaging
procedures, cardiac CT use has grown the most (7).
In clinical practice, CT imaging in patients with CRM
devices is frequently considered for a wide variety of
clinical indications and is often used as an alternative to
magnetic resonance imaging due to safety concerns (8–10).
The use of CT imaging was considered safe in such patients
until the 2008 FDA advisory. In the published data, mul-
tiple studies have evaluated the effect of radiation therapy
(11) and electromagnetic interference on the functioning of
CRM devices (12–20), but there exists much less published
peer-reviewed data about potential interference from CT
imaging (1,4,21,22), which raised concerns in the medical
community about the 2008 FDA recommendations. Only 2
small studies with limited in vivo data had led to the original
FDA advisory and recommendations (1,4). The ﬁrst study
(4) reported transient ventricular oversensing by PPMs in
two phantom models and in 6 of 11 patients exposed to CT
imaging; this ﬁnding was not associated with any signiﬁcant
clinical events or resetting of device programming. Impor-
tantly, device malfunction lasted for less than 4 s and was
limited to the period of direct exposure of the pulse gener-
ator to CT radiation beams (4). The second study (1)
exposed 13 PPMs and 8 ICDs, in an anthropomorphic
model, to standard and maximal possible radiation CT scans
(up to 90 mGy). The standard protocols included those
performed for coronary CT angiography (up to 66 mGy),
coronary artery calcium scoring (up to 15 mGy), detection of
pulmonary embolism (up to 20 mGy), and routine chest
CTs (up to 16 mGy). Ventricular oversensing with pacing
inhibition was detected in 20 and 17 devices with exposures
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device dysfunction lasted less than 4 s in most cases, and no
programming alterations occurred.
In response to the original 2008 FDA advisory, the
American Association of Physicists in Medicine (AAPM)
(5) expressed concerns that included, among others, a lack
of signiﬁcant peer-reviewed evidence to support the FDA
recommendations. The AAPM suggested that the advisory
overstates the potential risk relative to published data and
makes recommendations that may decrease the quality of
patient care by avoiding otherwise medically necessary CT
examinations, by decreasing the quality of medically neces-
sary examinations, and by potentially increasing patients’
anxiety, which may interfere with their care. The recom-
mendations by the FDA were considered by the AAPM to
possibly divert health care resources or increase costs by
implementing safety policies and procedures that have not
been demonstrated to be appropriate or necessary. Addi-
tional criticism was related to the fact that only 11 patients
were included in the peer-reviewed publications and that
interference was not observed in all of them. The AAPM
argued that most clinically indicated CTs do not involve
direct radiation of CRM devices for longer than 2 s and that
oversensing in the published reports was transient, without
any resetting of device programming, suggesting no long-
term effects.
Following the release of the original 2008 FDA advisory
report, 2 experimental studies addressed the interference of
CT imaging with the proper functioning of CRM
devices (21,22). These studies reproduced ﬁndings from the
original reports (21,22) and suggested that this interference
might be even less likely with clinical CT radiation doses
(21). Although irradiation at very high doses, such as in
patients receiving radiation therapy, interferes with PPMs
by producing electrical currents within the PPM semi-
conductor circuit (23), diagnostic-level radiation is generally
below the threshold at which such interference would occur
(24). With CT irradiation at typical clinical doses, inter-
ference is limited to transient oversensing, permanent
changes have not been demonstrated, and therapies from
devices with antitachycardia features are unlikely to occur
given that the dwell time of the radiation over the elec-
tronics module in the pulse generator would be <1 s in a
typical CT study. Although CT interference with cardiac
devices is more likely to be seen with diagnostic scans with
higher dose-length product (e.g., cardiovascular scans)
compared with the predominantly noncardiovascular scans
in the current report, the published data show that such
interference is very limited. Electrocardiogram gating is
typically associated with higher radiation doses, but the
FDA advisory made no distinction between routine chest
scans and electrocardiogram-gated studies. Extrapolation
from the previous FDA concerns would suggest that pa-
tients undergoing cardiac studies would be at increased risk.
However, no primary clinical outcomes were noted in our
study, regardless of the type of CT, supporting that thesestudies are not associated with higher clinical risk. Advances
in CT scanner technology have also further mitigated the
radiation effects of CT studies. Greater patient coverage in
z-axis is possible with newer-generation scanners with an
increased number of detectors and wider detector panels.
With the additional detectors, fewer rotations of the gantry
are necessary to image the entire heart, shortening image
acquisition time. Current studies demonstrate dose proﬁles
on par with or less than those of many conventional CT
studies (25). There is, therefore, increasing evidence to
suggest that CT interference with cardiac devices is even
less likely to be seen with modern scanners and protocols.
In March 2013, an updated FDA advisory report did not
emphasize routine device checks and speciﬁed that a staff
physician should be available when the CT involves scan-
ning over the device continuously for more than a few
seconds (2). However, despite the original and updated
advisory reports, no published peer-reviewed data exist
on the signiﬁcance of this interference in standard clinical
practice. The current study provides the ﬁrst clinical evi-
dence that performing clinically indicated CT imaging is
relatively safe in patients with CRM devices. The ﬁndings
support the recent updates to the FDA advisory and suggest
that the possibility of device reprogramming and inappro-
priate shocks, which are still highlighted in the current
version of the advisory, are not commonly observed with
routine clinically indicated CTs. However, a prudent
approach would be required in PPM-dependent patients
when CT scanning would involve continuous radiation of
the device for longer than a few seconds. The ﬁndings also
suggest that routine post-CT device checks, in the absence
of any suspicion of device dysfunction, are not
necessary. Importantly, the study reports on the magnitude
of the risks of exposing CRM devices to CT imaging in
clinical practice, including many device models from various
manufacturers, as well as a variety of protocols and radiation
doses from routine clinical settings and spanning the course
of a decade.
Study limitations. This study represents the largest report
to date on CT interference with CRM devices in vivo.
However, the study could have missed clinically signiﬁ-
cant events that would occur at very low incidence rates
(e.g., <1 of 500). However, it would require large national
databases to signiﬁcantly surpass the number of CTs
included in this study, and funding/execution of such a study
is unlikely. Additionally, the retrospective design of the
study may have missed transient interference (including
transient ventricular oversensing with pacing inhibition)
that may have happened at the time of CT imaging.
However, if present, those did not result in any clinically
signiﬁcant events at the time of CT. Given the small
number of devices that were exposed to multiple scans be-
tween consecutive interrogations, the study could not assess
the relationship between the number of scans and changes
in device parameters. However, none of the scans performed
between consecutive device interrogations were associated
JACC Vol. 63, No. 17, 2014 Hussein et al.
May 6, 2014:1769–75 CT Imaging Safety With Pacers and ICDs
1775with the primary outcome of interest. Finally, no measure-
ments of radiation doses were available, and it is possible
that higher radiation doses may have resulted in clinically
signiﬁcant effects. However, the vast majority of the scans
included in this report, similar to routine diagnostic CTs in
clinical practice, would have exposed the CRM device to
direct radiation beams for only a few seconds and did not
result in any adverse clinical events. The interference is
more likely to happen with higher dose-length product
scans, but given that this is transient and limited to over-
sensing for a few seconds with diagnostic scans, adverse
clinical events are very unlikely to occur. Furthermore, the
ﬁndings in the current report represent a wide array of CT
protocols that are most employed in clinical settings, and, as
previously discussed, radiation doses have dropped signiﬁ-
cantly with modern protocols and scanners.
Conclusions
The exposure of a large number of CRM devices to direct
radiation beams from CT imaging was not associated with
clinically signiﬁcant adverse events or alterations in pro-
grammed device settings or lead and generator parameters.
The ﬁndings suggest that the presence of CRM devices
should not delay or result in cancellation of clinically indi-
cated CT imaging procedures. Importantly, the study pro-
vides the ﬁrst evidence from clinical practice assessing such
interference and would be helpful when the FDA advisory
is re-evaluated.
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